Showing results (191-200 of 203) with videos related to
Sort By:
Pageof 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2024
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy OutcomesPriya Rastogi, Joyce O'Shaughnessy, Miguel Martin, et al.Nature Communications|March 9, 2024
Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trialLiang Huang, Da Pang, Hongjian Yang, et al.Proceedings of the National Academy of Sciences of the United States of America|May 31, 2014
Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signalingBhuvanesh Dave, Sergio Granados-Principal, Rui Zhu, et al.Nature Medicine|January 21, 2025
Pembrolizumab and chemotherapy in high-risk, early-stage, ER<sup>+</sup>/HER2<sup>-</sup> breast cancer: a randomized phase 3 trialFatima Cardoso, Joyce O'Shaughnessy, Zhenzhen Liu, et al.Annals of Translational Medicine|November 26, 2015
National consensus in China on diagnosis and treatment of patients with advanced breast cancerBinghe Xu, Xichun Hu, Zefei Jiang, et al.European Journal of Cancer (Oxford, England : 1990)|March 25, 2021
Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)Alvaro Moreno-Aspitia, Eileen M Holmes, Christian Jackisch, et al.The New England Journal of Medicine|December 6, 2018
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast CancerGunter von Minckwitz, Chiun-Sheng Huang, Max S Mano, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2020
Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III TrialJunjie Li, Keda Yu, Da Pang, et al.The New England Journal of Medicine|January 15, 2025
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast CancerCharles E Geyer, Michael Untch, Chiun-Sheng Huang, et al.The New England Journal of Medicine|June 3, 2021
Adjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast CancerAndrew N J Tutt, Judy E Garber, Bella Kaufman, et al.Pageof 21